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Abstract
Background: Tissue proteomic analysis of head and neck squamous cell carcinoma (HNSCC) and normal oral mucosa using
iTRAQ (isobaric tag for relative and absolute quantitation) labeling and liquid chromatography-mass spectrometry, led to
the identification of a panel of biomarkers including S100A7. In the multi-step process of head and neck tumorigenesis, the
presence of dysplastic areas in the epithelium is proposed to be associated with a likely progression to cancer; however
there are no established biomarkers to predict their potential of malignant transformation. This study aimed to determine
the clinical significance of S100A7 overexpression in HNSCC.
Methodology: Immunohistochemical analysis of S100A7 expression in HNSCC (100 cases), oral lesions (166 cases) and 100
histologically normal tissues was carried out and correlated with clinicopathological parameters and disease prognosis over
7 years for HNSCC patients. Overexpression of S100A7 protein was significant in oral lesions (squamous cell hyperplasia/
dysplasia) and sustained in HNSCC in comparison with oral normal mucosa (ptrend,0.001). Significant increase in nuclear
S100A7 was observed in HNSCC as compared to dysplastic lesions (p=0.005) and associated with well differentiated
squamous cell carcinoma (p=0.031). Notably, nuclear accumulation of S100A7 also emerged as an independent predictor of
reduced disease free survival (p=0.006, Hazard ratio (HR=7.6), 95% CI=1.325.1) in multivariate analysis underscoring its
relevance as a poor prognosticator of HNSCC patients.
Conclusions: Our study demonstrated nuclear accumulation of S100A7 may serve as predictor of poor prognosis in HNSCC
patients. Further, increased nuclear accumulation of S100A7 in HNSCC as compared to dysplastic lesions warrants a large-
scale longitudinal study of patients with dysplasia to evaluate its potential as a determinant of increased risk of
transformation of oral premalignant lesions.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer accounting for over 500,000 new cases
annually worldwide that includes sites in the oral cavity, pharynx
and larynx [1]. Squamous cell carcinoma of the oral cavity
accounts for two-thirds of the HNSCC cases occurring in
developing countries. The majority of oral squamous cell
carcinomas are preceded by visible changes of the oral mucosa.
Leukoplakia is the most commonly encountered oral lesion of the
oral cavity. These oral leukoplakia lesions show histological
evidence of squamous cell hyperplasia or dysplasia. The oral
lesions with histologically confirmed dysplasia are termed as oral
premalignant lesions (OPLs); on average, about one percent of oral
lesions transform into cancer annually [2–4]. Despite improve-
ment in treatment strategies, including surgery, radiotherapy (RT)
and/or chemotherapy (CT), the prognosis of OSCC patients
remains largely unsatisfactory, due to loco-regional recurrence.
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e11939The 5-year survival rate is less than 50%, and the prognosis of
advanced cases has not improved much over the past three
decades [5,6]. At present, the most important prognostic factors
include histological tumor grade, stage, depth of the tumor
invasion, and involvement of regional lymph nodes at the time of
diagnosis. In addition to these clinicopathological parameters,
molecular markers are being intensively sought and verified for
this malignancy. Lack of biomarkers for early detection and risk
assessment is clearly reflected by the fact that more than 50% of all
HNSCC patients have advanced disease at the time of diagnosis
[5].
In our recent study using iTRAQ (isobaric tag for relative and
absolute quantitation) labeling and multidimensional liquid
chromatography/tandem mass spectrometry (LC-MS/MS) for
examining differential protein expressions between HNSCC and
non-malignant tissues, we identified a panel of biomarker
candidates for this malignancy [7]. S100A7/psoriasin was
identified as overexpressed in HNSCC and emerged among the
panel of three best-performing potential biomarkers for distin-
guishing HNSCC from normal oral mucosa [7]. In another
independent study using iTRAQ, we also reported increased
expression of S100A7 protein in oral premalignant lesions
(dysplasia), albeit in only limited number of cases [8].
S100 protein family consists of at least 25 different types of low
molecular-weight proteins (9–13 kDa), which are characterized by
the presence of two calcium-binding sites of the EF-hand type
conformation [9–12]. S100A7 gene is located within the
‘epidermal differentiation complex’ on human chromosome
1q21 [13–16]. S100A7 protein , with a molecular weight of
11.4 kDa, was found to be upregulated in skin lesions of psoriatic
patients [17]. S100A7 is distributed in the cytoplasm of
keratinocytes in normal human epidermis and is present at the
cell periphery in terminally differentiated keratinocytes [18].
Increased S100A7 expression has been reported in several
epithelial malignancies such as, in situ ductal breast carcinoma,
lung, bladder, skin, esophageal and gastric cancer [19–24]. Altered
expression of S100A4 and S100A2 proteins has been associated
with prognosis in HNSCC [10,25–28]. S100A7 overexpression
has also been reported in a small set of HNSCC [29,30]. Although
increased expression of S100A7/psoriasin has been reported in
these studies, the impact of its expression on cancer development,
disease prognosis, and survival of HNSCC patients remains to be
completely determined. In this context our study assumes
importance, because of its retrospective nature, the large set of
patients representing different stages of HNSCC, and the long
term follow-up analysis. We analyzed the expression of S100A7/
psoriasin in HNSCC, oral lesions (with histological evidence of
squamous cell hyperplasia or dysplasia) and non-malignant oral
tissues by immunohistochemistry, determined its correlation with
clinicopathological parameters, and investigated its utility as a
prognostic marker for HNSCC.
Results
Immunohistochemical analysis of S100A7 expression in
oral leukoplakia lesions and cancers
To determine the clinical significance of S100A7 protein in
head-and-neck tumorigenesis, its expression was analyzed in
clinical specimens from HNSCC, oral leukoplakia lesions with
squamous cell hyperplasia or dysplasia, and histologically normal
tissues, using a specific monoclonal antibody by immunohisto-
chemistry. Figure 1A shows the total immunostaining score
distribution of nuclear/cytoplasmic S100A7 expression in oral
normal tissues, oral leukoplakia lesions with squamous cell
hyperplasia or dysplasia and HNSCC. Of the 100 normal tissues
analyzed, 84% did not show detectable S100A7 immunostaining
in nucleus/cytoplasm of the epithelial cells (Figure 1B(i)). In the
remaining normal tissues (16%), moderate cytoplasmic staining
was observed in differentiated epithelial cells in the suprabasal
layer only. Chi square trend analysis showed significant increase in
S100A7 expression (nuclear/cytoplasmic) in tissues obtained from
different stages of head-and-neck tumorigenesis (normal, squa-
mous cell hyperplasia, dysplasia and HNSCC; Table 1,
ptrend,0.001).
Oral leukoplakia lesions (squamous cell hyperplasia/
dysplasia). Of the 166 oral leukoplakia lesions analyzed, 97
cases (58.4%) showed significant increase in cytoplasmic S100A7
immunostaining (p,0.001, Odds ratio (OR)=7.4, 95%
CI=3.9213.7). Among these immunopositive cases 62 tissues
showed significant increase in nuclear S100A7 immunostaining
also (p,0.001, OR=11.3, 95% CI=4.3229.3) in comparison
with the normal tissues (Table 1). These 166 oral leukoplakia
lesions included 116 squamous cell hyperplasias; 54.3% (63/116)
cases showed significant increase in cytoplasmic S100A7
immunostaining (total score .3, p,0.001, OR=6.2, 95%
CI=3.2211.9) relative to the normal tissues (Table 1 and
Figure 1B(ii)). Significant increase in nuclear S100A7
immunostaining was also observed in 40/116 (34.5%) cases
(p,0.001, OR=10.0, 95% CI=3.8226.6). Notably, increased
cytoplasmic localization of S100A7 was observed in 68% dysplasia
(34 of 50 cases) (p,0.001, OR=11.2, 95% CI=5.0224.8) in
comparison with normal tissues (Table 1 and Figure 1B(iii)).
Similarly, progressive increase in nuclear expression of S100A7
was also observed in 22/50 (44%) dysplasia (p,0.001, OR=14.9,
95% CI=5.1243.0). Interestingly, S100A7 overexpression
(cytoplasmic/nuclear) was restricted to parabasal and suprabasal
layers only. None of these tissue sections showed S100A7
expression in proliferating layers in the basement membrane.
Mild membranous S1007 immunostaining (total score ,3) was
observed in 3 squamous cell hyperplasias, but in none of the
dysplasias analyzed.
HNSCC. zWe observed a similar pattern of S100A7
expression in HNSCC as well. Sixty seven out of 100 HNSCC
(67%) showed nuclear localization of S100A7 in tumor cells as
compared to the normal tissues (p,0.001, OR=38.6, 95%
CI=14.42103.9). Notably, significant increase in nuclear S100A7
expression was observed in HNSCC (67%) as compared to
dysplasia (44%) (p=0.005, OR=2.7, 95% CI=1.325.4). In
addition to nuclear staining, intense S100A7 staining was also
observed in the cytoplasm of tumor cells in 74 of 100 HNSCC
analyzed (p,0.001, OR=14.9, 95% CI=7.4229.9, Table 1 and
Figure 1B (iv)). The clinicopathological parameters of HNSCC
and their correlation with nuclear/cytoplasmic expression of
S100A7 are shown in Table 1. Interestingly, nuclear S100A7
overexpression showed an association with histopathological
differentiation of HNSCC (p=0.031). None of the HNSCC
tissues showed membranous S100A7 immunostaining. Majority
of the HNSCC tissues analyzed in this S100A7 immuno-
histochemistry study had more than 80% tumor cells in H&E
sections. However, there were five cases that showed dysplastic or
hyperplastic areas tissue adjacent to the tumor and these regions
showed immunostaining similar to that observed in the cases
that had only dysplasia or hyperplasia (Figure 1B (v). No
immunostaining was observed in HNSCC tissue sections used as
negative controls where the primary antibody was replaced by
isotype specific IgG (Figure 1B (vi)), while the positive control (ER-
negative breast cancer) showed S100A7 expression (Figure 1B
(vii)).
S100A7: Prognostic Marker
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PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e11939Figure 1. (A) Box-Plot analysis: Box plots showing distribution of total scores based on immunohistochemistry of S100A7 protein in
paraffin-embedded sections of oral normal tissues, squamous cell hyperplasia, dysplasia and HNSCC. The vertical axis shows the total
immunostaining score, obtained as described in the Methods section. (i) Nuclear S100A7 expression in squamous cell hyperplasia (IHC scoring range
0–7), dysplasia (range 0–7) and HNSCC (range 0–7) (b) cytoplasmic S100A7 in normal (range 0–7), squamous cell hyperplasia (range 0–7), dysplasia
(range 0–7) and HNSCC (range 0–7). (B) Immunohistochemical analysis of S100A7 in head-and-neck tissues. Paraffin-embedded
sections of histologically normal mucosa, squamous cell hyperplasia or with dysplasia, and HNSCC were stained using anti-S100A7
monoclonal antibody as described in the Methods section. (i) Normal oral mucosa showing no S100A7 immunostaining; (ii) squamous cell
hyperplasia showing nuclear and cytoplasmic S100A7 immunostaining; (iii) dysplasia depicting nuclear and cytoplasmic S100A7 immunostaining in
epithelial cells; (iv) HNSCC illustrating both intense cytoplasmic and nuclear staining in tumor cells; (v) HNSCC section with a dysplasia showing
S100A7 immunostaining in epithelial cells (original magnification6100); (vi) HNSCC used as a negative control, showing no S100A7 immunostaining
in tumor cells; and (vii) ER-negative breast cancer tissue showing S100A7 immunostaining. Arrows show nuclear and cytoplasmic localization (i-v, vii
original magnification 6200).
doi:10.1371/journal.pone.0011939.g001
Table 1. Analysis of S100A7 protein expression in Oral Lesions and its correlation with clinicopathological parameters.
Clinicopathological
Features
Total
Cases
Nuclear
N
Positivity
(%) p-value OR (95% CI)
Cytoplasmic
N
Positivity
(%) p-value OR (95% CI)
NORMAL 100 5 (5) 16 (16)
ORAL LESIONS (OL) 166 62 (37.3) ,0.001
5 11.3 (4.3229.3) 97 (58.4) ,0.001
6 7.4 (3.9213.7)
SQUAMOUS CELL
HYPERPLASIA
116 40 (34.5) ,0.001
7 10.0 (3.8226.6) 63 (54.3) ,0.001
8 6.2 (3.2211.9)
DYSPLASIA 50 22 (44.0) ,0.001
9 14.9 (5.1243.0) 34 (68.0) ,0.001
10 11.2 (5.0224.8)
HNSCC 100 67 (67.0) ,0.001
11 38.6 (14.42103.9) 74 (74.0) ,0.001
12 14.9 (7.4229.9)
Age (Median, 53 yrs)
(25–85 yrs)
,53 49 31 (63.3) 0.43 --- 35 (71.4) 0.566 ---
$53 51 36 (70.6) 39 (76.5)
Gender
Male 75 51 (68.0) 0.71 --- 58 (77.4) 0.188 ---
Female 25 16 (64.0) 16 (64.0)
Histological
Differentiation
Well 45 35 (77.8) 0.031
13 2.6 (1.126.6) 37 (84.1) 0.09 ---
Moderate 49 32 (65.3) 35 (71.4)
Poor 6 0 (0) 2 (33.3)
Tumor Size
T1+ T2 39 23 (59.0) 0.17 --- 24 (61.5) 0.02 2.8 (1.127.1)
T3 + T4 61 44 (72.1) 50 (82.0)
Nodal Status
N0 33 21 (63.6) 0.62 --- 22 (66.7) 0.241 ---
N1–4 67 46 (68.7) 52 (77.6)
*Habits
Non consumer 22 15 (68.2) 0.89 --- 15 (68.2) 0.69 ---
Tobacco consumer 78 52 (66.7) 59 (75.6)
Nuclear staining:
5Normal vs. oral lesions.
7Normal vs. squamous cell hyperplasia.
9Normal vs. dysplasia.
11Normal vs. HNSCC.
13Well differentiated SCCs vs Moderately and poorly differentiated SCCs; Squamous cell hyperplasia vs dysplasia, p=0.245; HNSCC vs dysplasia, p=0.005; N/OL/HNSCC:
ptrend,0.001.
Cytoplasmic staining:
6Normal vs oral lesions.
8Normal vs squamous cell hyperplasia.
10Normal vs Dysplasia.
12Normal vs. HNSCC; N/OL/HNSCC: ptrend,0.001; Squamous cell hyperplasia vs Dysplasia p=0.101.
*tobacco consumption habits include tobacco chewing and/or smoking of bidi or cigarettes, chewing of betel quid, areca nut or pan masala.
doi:10.1371/journal.pone.0011939.t001
S100A7: Prognostic Marker
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oral leukoplakia lesions and HNSCC
Receiver Operating Characteristic (ROC) analysis was used to
determine the potential of S100A7 overexpression to distinguish
squamous cell hyperplasia, dysplasia and HNSCC from normal
oral tissues. The values for area-under-the-curve (AUC) were
0.664, 0.691 and 0.824 for squamous cell hyperplasia (Figure 2a),
dysplasia (Figure 2b), and HNSCC (Figure 2c), respectively
(Table 2). Similarly, ROC analysis was used for determination
of AUC for cytoplasmic S100A7 staining in all these three groups
and area-under-the-curve (AUC) values were 0.650, 0.746 and
0.788 respectively as shown in Table 2 and Figure 2a–2c. The
positive predictive values (PPV) were 88.9, 81.5, and 93.1 for
nuclear immunostaining. Similarly, for cytoplasmic immunostain-
ing positive predictive values (PPV) were 79.8, 68.0, and 82.2 in
the three groups (Table 2).
Evaluation of S100A7 overexpression as prognostic
marker for HNSCC
The estimated predictive power of the marker i.e. the strength
of the statistical association of S100A7 expression with poor
prognosis was assessed by Kaplan-Meier survival analysis.
Kaplan–Meier survival analysis showed significantly reduced
disease-free survival (p=0.016; median survival 13 months) in
HNSCC patients harboring increased nuclear expression of
S100A7, compared with median disease-free survival of 70
months in the patients showing no nuclear S100A7 immunostain-
ing (Figure 3a). Similarly, reduced disease-free survival of 14
months was observed in HNSCC patients showing intense
cytoplasmic expression of S100A7, compared with patients who
did not show increased cytoplasmic S100A7 (median survival of 70
months, Figure 3b). Cox regression analysis was carried out to
determine the prognostic potential of S100A7 expression (nuclear/
cytoplasmic) for HNSCC in comparison with the other clinical
and pathologic parameters - histological grade, tumor size and
nodal status (Table 3). Nuclear S100A7 expression emerged as the
most significant prognostic marker for HNSCC (p=0.006,
Hazard’s ratio (HR) =7.6, 95% CI =1.3–5.1).
Based on our data, the additional prognostic value that nuclear
S100A7 expression provided for predicting cancerrecurrence(PPV)
in HNSCC patients was measured by the ratio: PPVrelapse/HNSCC
(83 months|S100A7)/PPVrelapse/HNSCC (83 months) =71.4/61.0;
or for excluding (NPV) cancer recurrence in HNSCC patients was
NPVrelapse/HNSCC (83 months|S100A7)/NPVrelapse/HNSCC (83
months) =57.1/39.0, as shown in Figure 3c and 3d respectively.
Verification of S100A7 overexpression by RT-PCR and
Western blotting
The overexpression of S100A7 in oral lesions was verified by
RT-PCR and Western blot analyses in the same representative
tissue samples as used for immunohistochemical analysis. RT-PCR
analysis demonstrated increased levels of S100A7 transcripts in
squamous cell hyperplasia, dysplasia, and HNSCC in comparison
with normal tissues (Figure 4a). Western blot analysis showed a
single intense band of 11.4 kDa, confirming the increased
expression in squamous cell hyperplasia, dysplasia and HNSCC,
as compared to the normal tissues (Figure 4b).
Discussion
The salient findings of our study are: (i) significant increase in
S100A7 expression (cytoplasmic/nuclear) in squamous cell
Figure 2. Receiver operating characteristic curves of S100A7 (nuclear/cytoplasmic) in (a) normal vs. squamous cell hyperplasia; (b)
normal vs. dysplasia; (c) normal vs. HNSCC. Bold line shows ROC analysis for nuclear S100A7. Dashed line shows ROC analysis for cytoplasmic
S100A7. Y-axis of the plot shows true-positive fraction and X-axis shows false positive fraction.
doi:10.1371/journal.pone.0011939.g002
Table 2. Biomarker Analysis of S100A7 (Nuclear/Cytoplasmic)
In Oral Lesions.
S100A7 Sensitivity Specificity PPV AUC
Nuclear Staining
Normal vs. squamous cell
hyperplasia
34.5 95.0 88.9 0.664
Normal vs. dysplasia 44.0 95.0 81.5 0.691
Normal vs. HNSCC 67.0 95.0 93.1 0.824
Cytoplasmic Staining
Normal vs. squamous cell
hyperplasia
54.3 84.0 79.8 0.650
Normal vs. dysplasia 68.0 84.0 68.0 0.746
Normal vs. HNSCC 74.0 84.0 82.2 0.788
doi:10.1371/journal.pone.0011939.t002
S100A7: Prognostic Marker
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oral tissues; (ii) cytoplasmic S100A7 expression distinguishes
squamous cell hyperplasia, dysplasia and HNSCC from normal
mucosa with high specificity and PPV; (iii) significant increase in
nuclear S100A7 accumulation in HNSCC as compared to
dysplasia; and (iv) potential of nuclear S100A7 as a marker of
poor prognosis of HNSCC. It is noteworthy that studies on
molecular analysis of oral leukoplakia lesions - with squamous cell
hyperplasia or dysplasia are very limited, often because these
patients do not seek medical attention, due to small lesions that do
not pose any serious clinical problems. Increased S100A7
expression has been reported in dysplastic lesions [29,30].
However, our data suggest S100A7 overexpression as early as in
squamous cell hyperplasia with no histological evidence of
Figure 3. Evaluation of S100A7 overexpression (nuclear/cytoplasmic) as a prognostic marker in HNSCC. Kaplan–Meier estimation of
cumulative proportion of disease-free survival: (a) Median time for disease-free survival (DFS; no recurrence/metastasis) in HNSCC patients showing
nuclear immunostaining of S100A7 was 13 months, whereas in patients showing no/faint S100A7 immunostaining in nucleus median DFS was 70
months (p=0.016); (b) In patients showing increased cytoplasmic S100A7 expression the median DFS was 14 months compared with HNSCC that
showed mild or moderate cytoplasmic immunostaining (median DFS =70 months, p=0.055). Time-dependent Positive and Negative Predictive
Values (PPV(t), NPV(t)) of nuclear S100A7 expression. (c) PPV(t) for time to cancer relapse for 49 HNSCC patients with S100A7
+ (solid line) and for all 77
HNSCC patients with survival data (dashed line); d) NPV(t) for time to cancer relapse for 28 HNSCC patients with S100A7
2 (solid line).
doi:10.1371/journal.pone.0011939.g003
Table 3. Correlation of Overall Survival with
Clinicopathological Parameters and S100A7 Expression:
Multivariate Analysis.
S. No.
Clinicopathological
parameter p-value HR (95% C.I.)
1 Histological differentiation 0.003 6.6 (1.224.1)
2 S100A7 (nuclear) 0.006 7.6 (1.325.1)
doi:10.1371/journal.pone.0011939.t003
S100A7: Prognostic Marker
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associated with chronic inflammation and the molecular links
between inflammation and pre-malignancy are being intensively
pursued. In this context, notably earlier studies have reported the
role of S100 proteins in inflammation, supporting our findings
[21,31–33]. S100A7 was identified in oral pre-malignant epithelia
(dysplasia) by microarray analysis and proposed to be a marker for
inflammation [34]. S100A7 has been shown to play a role in
facilitating the host inflammatory cell response, where it is
implicated as a chemotactic factor for lymphocytes and neutro-
phils in skin disease [35]. S100A7 has also been associated with
increased inflammatory cell infiltrates across all types of invasive
breast tumors [24]. In addition, S100A7 has been proposed as an
epidermal response gene to inflammatory cytokines [36,37]. In
breast cancer (DCIS), both oncostatin M (OSM) and interleukin-6
(IL-6) have been proposed to regulate the expression and activity
of S100A7 by regulating PI3K, STAT3 and Erk signaling [38].
These mechanisms may extend to HNSCC as well, since the
involvement of IL-6 and PI3K signaling in HNSCC has been well
documented by our laboratory and others [39,40].
A major clinical challenge faced by oncologists is the lack of
molecular markers to identify patients with oral leukoplakia lesions
that are at high risk of transformation to malignancy. In this
context, the significant increase in S100A7 expression observed in
HNSCCs (67% cases) as compared to the oral leukoplakia lesions
with dysplasia (44%) is an important finding of our study
(p=0.005, OR=2.8, 95% CI=1.425.7), suggesting that nuclear
accumulation of S100A7 may be linked to increased risk of
malignant transformation and might serve as a marker to identify
the high-risk lesions. Nevertheless, this finding warrants confirma-
tion in a longitudinal follow-up study of patients with oral
leukoplakia lesions, to establish a possible link between nuclear
S100A7 expression and risk of cancer development.
In our study, S100A7 was shown to be a prognostic factor for
reduced survival of HNSCC patients. However, in contrast to
these findings, the expression of this protein was associated with
high differentiation. None of the poorly differentiated specimens
(n=6), expressed S100A7. This finding seems to be contradictory
at a first glance. However, it is worthwhile to note that among
the 100 HNSCC cases analyzed in our study, only 6 poorly
differentiated tumors were analyzed; in comparison 45 well
differentiated tumors were investigated. Thus larger number of
poorly differentiated tumors needs to be analyzed to determine the
correlation with S100A7 expression in a future study. Our study
was also supported by an earlier report that showed association of
nuclear S100A7 expression with well differentiated squamous cell
carcinoma as compared to moderate and poorly differentiated
squamous cell carcinomas [30]. In a parallel study using OSCC
tissues sections, Kesting et al., [29] showed a significant correlation
between increased S100A7 expression and tumor stage (I and II),
well differentiated carcinomas and non-metastatic tumors, thus
supporting our findings. Similar observations have been reported
in bladder, breast and skin cancer [18,29,41–44]. S100A7
overexpression showed association with well differentiated squa-
mous cell carcinoma of the bladder in comparison the less
differentiated tumors. Similarly, S100A7 overexpression has been
shown to be expressed in the superficial, differentiated region of
the epithelium and its expression correlates with the degree of
keratinocyte differentiation [18]. S100A7 expression is relatively
low in normal, benign and atypical hyperplastic proliferative
ductal lesions, high in the pre-invasive ductal carcinoma in situ
(DCIS), but reduced in invasive carcinomas [41–44]. In skin
tumors, it is absent in undifferentiated basalioma and strongly
expressed in carcinoma in situ, as well as in keratoacanthoma and
differentiated squamous cell carcinoma. Taken together, these
findings clearly suggest the role of S100A7 in epithelial
differentiation. In an attempt to explain the role of S100A7,
Zhou et al. [30] demonstrated overexpression of S100A7 protein
resulted in degradation of b-catenin by non-canonical pathway
independent of GSK3b in oral cancer cells [30]. Further,
overexpression of S100A7 inhibited cell proliferation in vitro but
promoted tumor differentiation in an orthotopic xenograft oral
cancer model, supporting our clinical findings. Thus, S100A7
overexpression suppresses tumor growth and invasion by negative
regulation of b-catenin signaling. However, the exact mechanism
explaining this biphasic role of S100A7 expression in proliferation
in early stages but inducing differentiation in advanced stages in
head and neck carcinogenesis remains to be completely under-
stood and warrants further investigation.
Interestingly, S100A7 over expression (cytoplasmic/nuclear) has
been associated with poor patient outcome in ER-negative
invasive breast cancer patients [41,45]. Notably, our study showed
significance of nuclear S100A7 expression as a poor prognosticator
of HNSCC (independent of other clinical and pathological
parameters as revealed by Cox regression model). Further, our
time dependent predictive analysis also revealed poor prognosis of
HNSCC patients showing increased nuclear S100A7 expression.
Taken together, these findings demonstrated the potential of
nuclear S100A7 as a predictive marker for poor prognosis of
HNSCC. Altered expression of several S100 proteins has also been
associated with HNSCC [10,25–28]. Recently, both S100A4 and
S100A2 have been proposed as biomarkers of diagnostic and/or
prognostic relevance [26,46]. S100 family of proteins including
S100A7 have been shown to form both homodimers and
heterodimers interacting with cjun activation domain binding
protein 1 (Jab1), Ran binding protein M (RanBPM), epidermal
fatty acid binding protein (EFABP), and transglutaminase.
Figure 4. Verification of S100A7 expression in tissues. (a) RT-PCR
analysis of S100A7 in oral normal mucosa, squamous cell hyperplasia,
dysplasia and HNSCC tissues. For RT-PCR analysis and Western blot
analysis, we used normal (n=5), hyperplasia (n=5), dysplasia (n=5) and
HNSCC (n=5) tissues. Panel shows increased levels of S100A7
transcripts in oral lesions -squamous cell hyperplasia (H), dysplasia (D)
and HNSCC (T) compared with the oral normal mucosa (N) that showed
basal levels of S100A7 transcripts. b-actin used as a control to normalize
the quantity of RNA used for each RT-PCR reaction is shown in the
lower panel. (b) Western blot analysis of S100A7 in oral normal mucosa
(N), squamous cell hyperplasia (H), dysplasia (D) and HNSCC tissues.
Equal amount of protein lysates from these tissues were electropho-
resed on 12% SDS-PAGE and transferred to PVDF membrane. The
membrane was incubated with respective primary and secondary
antibodies as described in the Methods section and the signal detected
by enhanced chemiluminescence method. Panel shows increased
expression of S100A7 protein in oral lesions - squamous cell hyperplasia
(H), dysplasia (D) and HNSCC (T) compared with oral normal mucosa (N).
GAPDH was used as loading control.
doi:10.1371/journal.pone.0011939.g004
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migration of renal cancer cells [47], suggesting the potential for
S100A7 to influence invasive potential of cancer cells. Using 2D-
gel electrophoresis, S100A7 was identified as a putative marker for
lung SCC metastasis to brain [48]. Using in vivo models for
HNSCC loss of both S100A7 and E-FABP have been shown to
result in reduction of cell adhesion and increased cell motility,
leading to distant metastasis [49]. Thus, we speculate that with a
growing understanding of the role of S100A7 in cell migration,
invasion and proliferation pathways, S100A7 may serve as a
therapeutic target for the treatment of inflammation and cancer.
In conclusion, S100A7 was shown to be expressed in oral lesions
in early stages, prior to onset of dysplasia and in frank tumors. Its
subcellular localization, suggests that nuclear S100A7 may be
associated with increased risk of transformation of oral pre-
malignant lesions and recurrence in HNSCC. Furthermore,
increased nuclear accumulation of S100A7 in HNSCC as
compared to dysplastic lesions warrants a large-scale longitudinal
study of patients with dysplasia to evaluate its potential as a
determinant of increased risk of transformation of oral premalig-
nant lesions and recurrence in HNSCC.
Materials and Methods
Patients and clinicopathological data collection, tissue
specimens
The Institutional Human Ethics Committee of the All India
Institute of Medical Sciences (AIIMS), New Delhi, India,
approved this study prior to its commencement. Tissue specimens
were obtained by diagnostic or therapeutic procedures from 166
patients with oral lesions- clinically defined leukoplakia [with
squamous cell hyperplasia (n=116) or with dysplasia (n=50)]
attending the Outpatient Clinic of the Departments of Surgical
Disciplines and Otorhinolaryngology, AIIMS, and from 100
HNSCC patients undergoing curative cancer surgery during the
period 2002–2007, after obtaining the patients’ written consent.
Wherever possible, non-malignant tissues (n=43) were taken each
from a site distant from the surgically resected HNSCC. Non-
malignant oral tissues (n=57) were also collected from the patients
attending the Outpatient Department of Dental Surgery for tooth
extraction, after obtaining the patients’ written consent. Taken
together, these 100 non-malignant oral tissues with histological
evidence of normal epithelia constituted the normal group. After
excision, tissues were immediately snap-frozen in liquid nitrogen
and stored at 280uC in the Research Tissue Bank till further use;
one part of the tissue was collected in 10% formalin and
embedded in paraffin for histopathological and immunohisto-
chemical analyses. Histologically confirmed oral normal epithelia,
squamous cell hyperplasia, dysplasia, and HNSCC as revealed by
H & E staining were used for immunohistochemistry [7]. Patient
demographic, clinical, and pathological data were recorded in a
pre-designed performa as described previously [7,50]. The
information documented included clinical TNM staging (tumor,
node, and metastasis based on the Union International Center le
Cancer TNM classification of malignant tumors 2002), site of the
lesion, histopathological differentiation, age, gender, and tobacco
consumption habits.
Follow-up Study
Seventy-seven HNSCC patients who underwent treatment from
2002–2007 were investigated and evaluated in the head-and-neck
cancer follow-up clinic at regular time intervals. Survival status of
the HNSCC patients was verified and updated from the records of
the Tumor Registry, Institute Rotary Cancer Hospital, AIIMS, as
of December 2009. HNSCC patients were monitored for a
maximum period of 83 months. Disease-free survivors were
defined as patients free from clinical and radiological evidence of
local, regional, or distant relapse at the time of the last follow-up
[50,51]. Loco-regional relapse/death were observed in 51 of 77
(66%) patients monitored during the follow-up. Twenty six
patients who did not show recurrence were alive until the end of
the follow-up period. Only disease-free survival was evaluated in
the present study, as the number of deaths due to disease
progression did not allow a reliable statistical analysis. Disease-free
survival was expressed as the number of months from the date of
surgery to loco-regional relapse/death.
Immunohistochemistry
Paraffin-embedded sections (5 mm) of human oral non-malig-
nant tissues (n=100), oral lesions [squamous cell hyperplasia
(n=116) or with dysplasia (n=50)] and HNSCC (n=100) were
collected on gelatin-coated slides. In brief, the sections were
deparaffinized in xylene, hydrated in gradient alcohol, and pre-
treated in a microwave oven for 10 min at 800 W and 5 min at
480 W in citrate buffer (0.01 M, pH=6.0) for antigen retrieval.
The sections were incubated with hydrogen peroxide (0.3% v/v) in
methanol for 30 min to quench the endogenous peroxidase
activity, followed by blocking with 1% bovine serum albumin
(BSA) to preclude nonspecific binding. Thereafter, the slides were
incubated with mouse monoclonal anti-S100A7 antibody (0.5 mg/
ml, sc-52948, Santa Cruz Biotechnology, CA) for 16 h at 4uC.
The primary antibody was detected using the streptavidin-biotin
complex with the Dako LSAB plus kit (Dako Cytomation,
Glostrup, Denmark) and diaminobenzidine as the chromogen as
described before [7,8]. In the negative control tissue sections, the
primary antibody was replaced by isotype specific non-immune
mouse IgG. A section from estrogen receptor (ER)-negative breast
cancer tissue was used as a positive control in each batch of
immunohistochemistry.
Evaluation of immunohistochemical staining
Each slide was evaluated for S100A7 immunostaining using a
semi-quantitative scoring system for both staining intensity and the
percentage of positive epithelial cells [8]. For S100A7 protein
expression, sections were scored as positive if epithelial cells
showed immunopositivity in the nucleus/cytoplasm when ob-
served independently by four of us (SCT, AM, JK, SDG), who
were blinded to the clinical outcome (the slides were coded and the
scorers did not have prior knowledge of the local tumor burden,
lymphonodular spread, and grading of the tissue samples). The
tissue sections were scored based on the % of immunostained cells
as: 0–10%=0; 10–30%=1; 30–50%=2; 50–70%=3 and 70–
100%=4. Sections were also scored semi-quantitatively on the
basis of staining intensity as negative =0; mild =1; moderate =2;
intense =3 [50,51]. Finally, a total score was obtained by adding
the score of percentage positivity and intensity. In cases where
both nuclear and cytoplasmic immunoreactivity was observed, the
nuclear and cytoplasmic staining was scored independently. The
scoring by the four observers was discrepant in about 5% cases
and a consensus on the final result was reached by re-evaluation of
these slides and discussion.
Statistical Analyses
The immunohistochemical data were subjected to statistical
analyses using the SPSS 10.0 software (Chicago). Sensitivity and
specificity were calculated and quantified using receiver operating
characteristic (ROC) analyses. The predictive value (PV) describes
the proportion of correctly classified cases. Based on sensitivity and
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criterion for both cytoplasmic and nuclear S100A7 immunoposi-
tivity for statistical analyses. The relationships between S100A7
protein expression and clinicopathological parameters were tested
using Chi-Square and Fischer’s exact test. Two-sided p values
were calculated and p,0.05 was considered to be significant.
Similarly, positive predictive value (PPV) was calculated for oral
leukoplakia and HNSCC with respect to normal tissues.
The correlation of S100A7 staining with patient survival was
evaluated using life tables constructed from survival data with
Kaplan-Meier plots [50,51]. Multivariate analysis was carried out
using Cox regression model. The systematic and rigorous
assessment of Positive and Negative Predictive Values (PPV and
NPV respectively) for prognostic biomarkers was carried out as
described earlier by us [50]. For the follow-up study of HNSCC,
let T denote the failure time, i.e., the first time recurrence is
diagnosed after surgical removal of the tumor. For these data, the
positive and negative predictive values as functions of time are
defined as follows:
PPVtumor(t) = Prob (T # t AND Recurrence| S100A7 (nuclear)
$3);
NPVtumor(t) = Prob (T . t OR No Recurrence| S100A7
(nuclear) ,3); 0# t #83
These probabilities are estimated from the observed accumu-
lated incidences over the respective time periods.
Verification of S100A7 expression using Reverse
Transcription-PCR and Western blotting
Representative frozen tissue specimens of histologically con-
firmed oral normal tissues (n=5), squamous cell hyperplasia
(n=5), dysplasia (n=5), and HNSCC (n=5) were used for
extraction of total RNA using the TRI reagent (Sigma, MO) as
previously described [7,52]. First-strand cDNA was synthesized
using 2 mg RNA with oligo dT as the primer with MMLV reverse
transcriptase. PCR was carried out using S100A7 specific primers
forward (59-CTTCCTTAGTGCCTGTGACAAAAA-39) and re-
verse (59-AAGGACAGAAACTCAGAAAA ATCAATCT-39) and
PCR product was visualized on agarose gel with UV light.
Western blotting was carried out using whole-cell lysates in same
tissue samples as used for RT-PCR as described earlier [7,8].
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